- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04221087
Steroid Use in Non-RSV Bronchiolitis
March 15, 2023 updated by: Allison Williams
Dexamethasone Use for the Treatment of Non-RSV Bronchiolitis
The proposed study is a pilot randomized control trial to determine the efficacy of dexamethasone use in hospitalized children who are less than 2 years of age with non-respiratory syncytial virus (RSV) bronchiolitis admitted to the University of Pittsburgh Medical Center (UPMC) Children's Hospital of Pittsburgh from February 1 to May 31, 2022.
It is hypothesized that the use of standard airway-dose steroids (0.6mg/kg dexamethasone) will improve the clinical outcome of children hospitalized for non-RSV bronchiolitis, which will be evident by decreased length of stay.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
The study will take place at UPMC Children's Hospital of Pittsburgh with patients admitted to the general pediatric service.
The attending physician on the clinical service team will identify patients diagnosed with bronchiolitis.
If the participant meets inclusion and exclusion criteria, a member from the study team will then meet with the participant's family to discuss the study and obtained informed consent.
A participant may have had a rapid RSV/influenza testing already complete for clinical purposes.
If this has been done, participants will be asked to obtain a secondary nasopharyngeal swab so that it may be tested for a full respiratory viral panel for statistical stratification.
Once rapid testing is obtained and results are negative for both RSV and influenza, the participant will then be randomized to either the intervention (dexamethasone) or control (placebo) arm of the study.
Study members will calculate a modified Tal score (MTS) at time of consent and then 12-24 hours after medication administration.
Throughout admission, participants will also receive standard of care for bronchiolitis, which may include regular vital sign evaluation, supplemental oxygen, intravenous fluids or nasogastric tube feedings, and anti-pyretic therapy.
Because this is a pilot study, the study will be underpowered, however, this study will provide data that will allow the investigators to estimate the sample size needed for a future study.
The number of time points to be used for the generalized estimating equation can be determined ad hoc to include a reasonably balanced sample to make the comparison valid.
Study Type
Interventional
Enrollment (Actual)
3
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
- UPMC Children's Hospital of Pittsburgh
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 day to 2 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Less than or equal to 24 months
- First episode of wheezing or first clinical diagnosis of bronchiolitis
- Admitted to the general pediatric service at UPMC Children's Hospital of Pittsburgh
- Ability of a parent or guardian to understand and comply with the study procedures
- Signed written informed consent by parent or guardian
Exclusion Criteria:
- Preterm birth < 35 weeks
- Presence of underlying cardiopulmonary, neuromuscular, or other complex disease
- Admission to the pediatric intensive care unit
- Co-infection with influenza infection or concomitant bacterial infection (such as pneumonia or AOM)
- History of allergy or reaction to steroids
- History of an underlying chronic medical condition -including chronic heart disease, chronic lung disease (except asthma),congenital anomalies of the airways or lung, cystic fibrosis, chronic renal disease including nephrotic syndrome, protein losing enteropathy of any cause, severe malnutrition, neurocognitive disorders, metabolic disorders (including phenylketonuria), or genetic disorders (note: genetic syndromes such as Down syndrome and Edwards Syndrome are excluded; however, children with genetic disorders (e.g., hemophilia) but who do not have a genetic syndrome may not satisfy this particular exclusion criterion; it is important that children with such genetic disorders do not have symptoms and/or comorbidities that would pose additional risk to them nor jeopardize the adequacy of study assessments.")
- History of a condition that compromises the immune system - human immunodeficiency virus infection, primary immunodeficiency, anatomic or functional asplenia; receipt of a hematopoietic stem cell or solid organ transplant at any time; receipt of immunosuppressive therapy including chemotherapeutic agents, biologic agents, antimetabolites or radiation therapy during the past 12 months; or daily use of systemic corticosteroids for more than 7 consecutive days during the past 14 days.
- Any other condition that in the judgment of the investigator precludes participation because it could affect the safety of the subject
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo Arm
Participants will be given a placebo of sugar water (0.6ml/kg/dose) in a single oral dose and standard of care for bronchiolitis (supplemental oxygen, antipyretics, suctioning etc.)
|
Sugar water based on same ml dosing of intervention arm drug
Other Names:
|
Experimental: Dexamethasone Arm
Participants will be given dexamethasone (0.6mg/kg/dose) in a single oral dose in addition to the standard of care for bronchiolitis (supplemental oxygen, antipyretics, suctioning etc.)
|
0.6mg/kg/dose - single oral dose administration to intervention arm
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hospital Length of Stay
Time Frame: Admission vitals through discharge paperwork printing time, average of 24-96 hours
|
Measurement of hospital length of stay in hours
|
Admission vitals through discharge paperwork printing time, average of 24-96 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Severity of Bronchiolitis
Time Frame: Will obtain MTS upon admission by chart view or, if unable, at time of enrollment, and compare to MTS obtained 12 hours after medication administration
|
Measurement of reducing severity of bronchiolitis by assessment with modified TAL score (MTS)
|
Will obtain MTS upon admission by chart view or, if unable, at time of enrollment, and compare to MTS obtained 12 hours after medication administration
|
Severity of Bronchiolitis
Time Frame: Will compare respiratory assessment via MTS 12 hours after admission and at discharge, average of 24-96 hours from admission
|
Measurement of reducing severity of bronchiolitis by assessment with modified TAL score (MTS)
|
Will compare respiratory assessment via MTS 12 hours after admission and at discharge, average of 24-96 hours from admission
|
Severity of Bronchiolitis
Time Frame: Admission to time of discharge to home or transfer to ICU or acute care floor, usual time frame is 24-72 hours
|
Measurement of reducing severity of bronchiolitis by evaluation of patient outcome - discharge, transfer to ICU or acute care floor
|
Admission to time of discharge to home or transfer to ICU or acute care floor, usual time frame is 24-72 hours
|
7-day Same-Cause Revisit Rate
Time Frame: Discharge to 7 days
|
Measuring number of revisits to the primary care physician or emergency room or re-admission to the hospital for ongoing bronchiolitis related symptoms within 7 days of discharge
|
Discharge to 7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Allison E Williams, MD, University of Pittsbrgh, UPMC Children's Hospital of Pittsburgh
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 3, 2020
Primary Completion (Actual)
December 31, 2022
Study Completion (Actual)
December 31, 2022
Study Registration Dates
First Submitted
December 29, 2019
First Submitted That Met QC Criteria
January 5, 2020
First Posted (Actual)
January 9, 2020
Study Record Updates
Last Update Posted (Actual)
March 21, 2023
Last Update Submitted That Met QC Criteria
March 15, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Bronchial Diseases
- Lung Diseases, Obstructive
- Bronchitis
- Bronchiolitis
- Bronchiolitis, Viral
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
Other Study ID Numbers
- STUDY19080287
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchiolitis, Viral
-
Guy's and St Thomas' NHS Foundation TrustCompletedAcute Viral BronchiolitisUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisCompletedAcute Viral BronchiolitisFrance
-
Ministry of Health, SpainCompleted
-
Hospices Civils de LyonRecruiting
-
Assistance Publique - Hôpitaux de ParisCompletedSevere Viral BronchiolitisFrance
-
Groupe Hospitalier du HavreCompletedAcute Viral BronchiolitisFrance
-
Laval UniversityCanadian Institutes of Health Research (CIHR); Centre de Recheche du Centre...WithdrawnAcute Viral Bronchiolitis.Canada
-
Pontificia Universidade Católica do Rio Grande...CompletedAcute Viral Bronchiolitis
-
Assistance Publique Hopitaux De MarseilleUnknown
-
Hillel Yaffe Medical CenterCompletedReflexology | Bronchiolitis; ChemicalIsrael
Clinical Trials on Placebos
-
Yiling Pharmaceutical Inc.Completed
-
Nova Scotia Health AuthorityRecruiting
-
Beth Israel Deaconess Medical CenterTerminated
-
Intra-Cellular Therapies, Inc.CompletedBipolar Depression | Major Depressive DisorderUnited States, Bulgaria, Russian Federation, Serbia, Ukraine
-
Josef Smolen, Univ. Prof. Dr.Unknown
-
GE HealthcareSyneos HealthTerminatedChronic Kidney DiseasesUnited States, Spain, Belgium, Canada, Poland, United Kingdom
-
Viela BioCTI Clinical Trial and Consulting ServicesTerminated
-
Nanjing Sanhome Pharmaceutical, Co., Ltd.Completed
-
Viking Therapeutics, Inc.Active, not recruitingNASH - Nonalcoholic SteatohepatitisUnited States, Belgium, France, Mexico, Puerto Rico
-
Shengjing HospitalEnrolling by invitation